Načítá se...

Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment

PURPOSE: We assessed pulmonary toxicity of cyclin-dependent kinase (CDK)4/6 inhibitors by analyzing the publicly available FDA Adverse Event Reporting System (FAERS). METHODS: Reports of interstitial lung disease (ILD) were characterized in terms of demographic information, including daily dose, lat...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Breast Cancer Res Treat
Hlavní autoři: Raschi, Emanuel, Fusaroli, Michele, Ardizzoni, Andrea, Poluzzi, Elisabetta, De Ponti, Fabrizio
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer US 2020
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7641870/
https://ncbi.nlm.nih.gov/pubmed/33150548
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-020-06001-w
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!